TY - JOUR
T1 - Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis
AU - Lauzier, François
AU - Arnold, Donald M.
AU - Rabbat, Christian
AU - Heels-Ansdell, Diane
AU - Zarychanski, Ryan
AU - Dodek, Peter
AU - Ashley, Betty Jean
AU - Albert, Martin
AU - Khwaja, Kosar
AU - Ostermann, Marlies
AU - Skrobik, Yoanna
AU - Fowler, Robert
AU - McIntyre, Lauralyn
AU - Nates, Joseph L.
AU - Karachi, Tim
AU - Lopes, Renato D.
AU - Zytaruk, Nicole
AU - Finfer, Simon
AU - Crowther, Mark
AU - Cook, Deborah
N1 - Funding Information:
Funding sources F Lauzier is a recipient of a research career award from the Fonds de la recherche du Québec-Santé. DM Arnold holds a New Investigator Award from the Canadian Institutes of Health Research in partnership with Hoffmann-LaRoche. R Zarychanski receives salary support from CIHR as part of an RCT Mentoring Award. R Fowler is a Clinician Scientist of the Heart and Stroke Foundation of Ontario. M Crowther holds a Career Investigator Award from the Heart and Stroke Foundation of Ontario and the Leo Pharma Chair in Thromboembolism Research at McMaster University and St Joseph’s Healthcare, Hamilton. L McIntyre holds a New Investigator Award from the Canadian Institute of Health Research/Canadian Blood Services. D Cook is a Research Chair of the Canadian Institutes of Health Research. The list of PROTECT collaborators is available in the Supplement Digital Content. This study was funded by the Canadian Institute Health Research (#MCT78568), Heart & Stroke Foundation of Canada (#T6157, #T6950, #NA6186) and the Australian and New Zealand College of Anesthetists Research Foundation (#07/23).
Funding Information:
Acknowledgments The authors are very grateful to the research coordinators for their help with this trial. The trial was designed by the PROTECT (Prophylaxis for ThromboEmbolism in Critical Care Trial) Steering Committee, PROTECT investigators, and the Canadian Critical Care Trials Group. PROTECT was supported by the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. The list of PROTECT collaborators is provided in the Electronic Supplementary Material.
PY - 2013/12
Y1 - 2013/12
N2 - Purpose: Bleeding frequently complicates critical illness and may have serious consequences. Our objectives are to describe the predictors of major bleeding and the association between bleeding and mortality in medical-surgical critically ill patients receiving heparin thromboprophylaxis. Methods: We prospectively studied patients from 67 intensive care units and six countries enrolled in a thromboprophylaxis trial (NCT00182143) comparing dalteparin with unfractionated heparin. Patients with trauma, orthopedic surgery or neurosurgery were excluded. Trained research coordinators used a validated tool to document bleeding, which underwent duplicate independent blinded adjudication. Major bleeding was defined as hypovolemic shock, bleeding into critical sites, requiring an invasive intervention or transfusion of at least two units of red blood cells, or associated with hypotension or tachycardia in the absence of other causes. Adjusted Cox proportional hazard regression analysis was used to identify major bleeding predictors and the association between bleeding and mortality. Results: Among 3,746 patients, bleeding occurred in 208 [5.6 %, 95 % confidence interval (CI) 4.9-6.3 %]. Time-dependent predictors were prolonged activated partial thromboplastin time [hazard ratio (HR) 1.10, 1.05-1.14 per 10 s increase], lower platelet count (HR 1.16, 1.09-1.24 per 50 × 10 9/L decrease), therapeutic heparin (HR 3.26, 1.72-6.17), antiplatelet agents (HR 1.38, 1.02-1.88), renal replacement therapy (HR 1.75, 1.20-2.56), and recent surgery (HR 1.64, 1.01-2.65). Type of pharmacologic thromboprophylaxis was not associated with bleeding. Patients with bleeding had a higher risk of in-hospital death (HR 2.09, 1.69-2.57). Conclusions: As major bleeding has modifiable risk factors and is associated with in-hospital mortality, strategies to mitigate these factors should be evaluated in critically ill patients.
AB - Purpose: Bleeding frequently complicates critical illness and may have serious consequences. Our objectives are to describe the predictors of major bleeding and the association between bleeding and mortality in medical-surgical critically ill patients receiving heparin thromboprophylaxis. Methods: We prospectively studied patients from 67 intensive care units and six countries enrolled in a thromboprophylaxis trial (NCT00182143) comparing dalteparin with unfractionated heparin. Patients with trauma, orthopedic surgery or neurosurgery were excluded. Trained research coordinators used a validated tool to document bleeding, which underwent duplicate independent blinded adjudication. Major bleeding was defined as hypovolemic shock, bleeding into critical sites, requiring an invasive intervention or transfusion of at least two units of red blood cells, or associated with hypotension or tachycardia in the absence of other causes. Adjusted Cox proportional hazard regression analysis was used to identify major bleeding predictors and the association between bleeding and mortality. Results: Among 3,746 patients, bleeding occurred in 208 [5.6 %, 95 % confidence interval (CI) 4.9-6.3 %]. Time-dependent predictors were prolonged activated partial thromboplastin time [hazard ratio (HR) 1.10, 1.05-1.14 per 10 s increase], lower platelet count (HR 1.16, 1.09-1.24 per 50 × 10 9/L decrease), therapeutic heparin (HR 3.26, 1.72-6.17), antiplatelet agents (HR 1.38, 1.02-1.88), renal replacement therapy (HR 1.75, 1.20-2.56), and recent surgery (HR 1.64, 1.01-2.65). Type of pharmacologic thromboprophylaxis was not associated with bleeding. Patients with bleeding had a higher risk of in-hospital death (HR 2.09, 1.69-2.57). Conclusions: As major bleeding has modifiable risk factors and is associated with in-hospital mortality, strategies to mitigate these factors should be evaluated in critically ill patients.
KW - Critical care
KW - Embolism
KW - Hemorrhage
KW - Heparin
KW - Mortality
KW - Platelet aggregation inhibitors
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=84888198961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888198961&partnerID=8YFLogxK
U2 - 10.1007/s00134-013-3044-3
DO - 10.1007/s00134-013-3044-3
M3 - Article
C2 - 23942857
AN - SCOPUS:84888198961
SN - 0342-4642
VL - 39
SP - 2135
EP - 2143
JO - Intensive Care Medicine
JF - Intensive Care Medicine
IS - 12
ER -